AstraZeneca gets CDSCO Panel nod to study Budesonide, Glycopyrronium and Formoterol Fumarate

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-10-20 12:15 GMT | Update On 2024-10-20 12:15 GMT

New Delhi: The drug major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the phase III clinical study of Budesonide, Glycopyrronium, and Formoterol Fumarate.

This came after the firm presented Phase III clinical study protocol No. : D5989C00001: CSP Version 2.0 dated 28 Jan 2024. Addendum IND-1, Version 1.0, 10 Jan 2024.

This is a randomized, double-blind, parallel-group, multi-center, Phase III study to assess the efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhalers relative to Glycopyrronium and Formoterol Fumarate MDI on cardiopulmonary outcomes in Chronic Obstructive Pulmonary Disease.

Budesonide, glycopyrrolate, and formoterol combination is used as long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This medicine helps improve and reduce the number of flare-ups of the symptoms of COPD.

Inhaled budesonide belongs to the family of medicines known as corticosteroids (cortisone-like medicines). It works by preventing inflammation (swelling) in the lungs that causes an asthma attack.

Glycopyrrolate and formoterol are long-acting bronchodilators. Bronchodilators are medicines that are breathed in through the mouth to open up the bronchial tubes (air passages) in the lungs. They relieve coughing, wheezing, and trouble breathing by increasing the flow of air through the bronchial tubes.

At the recent SEC meeting for pulmonary held on 3rd October 2024, the expert panel reviewed the Phase III clinical study protocol No. : D5989C00001: CSP Version 2.0 dated 28 Jan 2024. Addendum IND-1, Version 1.0, 10 Jan 2024.

After detailed deliberation, the committee recommended a grant of permission to conduct the trial as presented by the firm.

Also Read:Soon, harsher penalties for submitting false data for drug approval

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

AstraZeneca gets CDSCO Panel nod to study Budesonide, Glycopyrronium and Formoterol Fumarate

Similar News

Four senior employees of Medley Pharma booked over Palghar gas leak

Kotapally raid: Large cache of medicines bound for Maharashtra confiscated

Ravenbhel's Bilastine, Montelukast FDC Under Review, CDSCO Panel Seeks Pediatric Expert Opinion

From Breakthrough to Backlash: Novo Nordisk's Ozempic Faces USD 2 Billion Lawsuit

Aurobindo Pharma Clarifies Zentiva Acquisition Reports 'Premature', No Binding Pact Finalised

CDSCO Digitisation Cuts Post-Approval Change Timelines in CGTs from 218 to 98 Days: DCGI

PLI scheme brings down cost of rare disease treatment from crores to lakhs

Aurobindo Pharma in lead to acquire Zentiva for US 5.5 billion: ET Report